The blockade of serotonin (5-HT) and norepinephrine (NE) transporters in vitro and in vivo by the dual 5-HT
Serotonin (5-HT) and norepinephrine (NE) neuronal pathways in the central nervous system are involved in the mechanism of action of antidepressant drugs and, additionally, they may be involved in the pathogenesis of depression (Schildkraut 1965; Blier and de Montigny 1994; Delgado et al. 1990 Delgado et al. , 1993 . However, antidepressant therapies that activate 5-HT or NE pathways have a latency of two to three weeks in response and only about 70-80% of patients are responders (Roose et al. 1986; Thase and Rush 1995) . Clinical studies have indicated that combination therapy with drugs that inhibit 5-HT and NE uptake and thereby enhance activity of both neuronal systems may have improved therapeutic efficacy and possibly a faster onset of activity compared to drugs that inhibit only one monoamine uptake system (Weilburg et al. 1989; Nelson et al. 1991; Seth et al. 1992 ). The tertiary amine containing tricyclic antidepressants such as imipramine and amitriptyline inhibit both NE and 5-HT uptake in vitro to variable degrees and therefore may be considered dual uptake inhibitors. However, in vivo imipramine and amitriptyline are rapidly metabolized to secondary amines that are potent and selective NE uptake inhibitors and no longer inhibit uptake of both monoamines . Furthermore, the tricyclic antidepressants are also antagonists at a number of neuronal receptors including muscarinic, ␣ -adrenergic and histamine H 1 receptors, which causes significant side effects . Studies comparing the efficacy of tricyclic antidepressants with selective 5-HT reuptake inhibitors (SSRI) suggest that tricyclic antidepressants may be slightly more efficacious (Nelson 1998; Anderson 2000) but, arguably, compounds with adequate dual uptake inhibition have not been thoroughly evaluated clinically. In order to test the hypothesis that agents endowed with the ability to block both 5-HT and NE uptake would have supplemental efficacy in the treatment of depression, compounds such as duloxetine (Wong et al. 1993; Wong 1998 ) and venlafaxine (Muth et al. 1986 ; for review see Artigas 1995) with combined 5-HT and NE uptake inhibitor (SNRI) properties in a single molecule have been developed. Duloxetine and venlafaxine have both been shown to be clinically effective antidepressants (Berk et al. 1997; Mendels et al. 1993; Schweizer et al. 1994) .
Duloxetine potently inhibits 5-HT and NE uptake processes in vitro and in vivo at similar doses (Kasamo et al. 1996; Béïque et al. 1998; Wong et al. 1993; Wong 1998) . However, venlafaxine has been shown to display relatively low affinity for NE uptake into rat synaptosomes compared to 5-HT uptake and for the human NE transporter versus the 5-HT transporter (Bolden-Watson and Richelson 1993; Béïque et al. 1998; Tatsumi et al. 1997) . In vivo , intravenously administered venlafaxine was about 10 times more potent at prolonging recovery of firing activity of dorsal hippocampal neurons after microiontophoretically applied 5-HT than NE (Béïque et al. 1998 ). In addition, venlafaxine after intravenous administration was about 3-fold more active at suppressing firing activity of 5-HT neurons in the dorsal raphe compared to NE neurons in locus coeruleus. Thus, it has been pointed out that there is a discrepancy between in vitro and in vivo potencies of venlafaxine for the effects on the noradrenergic neurons (Béïque et al. 1999) . To further address this issue, this study compared the affinity of the two compounds for human and rat 5-HT, NE, and DA transporters and blockade of 5-HT and NE uptake into rat synaptosomes. The ability of the two drugs to block 5-HT and NE transporters ex vivo and block the monoamine depletion induced by 5-HT and NE transporter-specific neurotoxins was also investigated. Finally, the selectivity of duloxetine and venlafaxine was investigated by determining the inhibition of radioligand binding to a number of neuronal receptors.
METHODS

Transporter Binding
Membranes from HEK 293, MDCK and HEK293 cell lines transfected with human 5-HT, NE and DA transporters, respectively, were obtained from Receptor Biology, Inc. (Beltsville, MD). All assays were performed in triplicate in a final volume of 0.8 ml containing each of the following: 0.2 ml of various concentrations of drug in buffer (50 mM Tris Cl pH 7.4, 150 mM NaCl, and 5 mM KCl for 5-HT and NE transporters; 50 mM Tris Cl, pH 7.4, and 100 mM NaCl for the DA transporter); 0. Ci/mmol, New England Nuclear) in buffer for the human 5-HT, NE and DA transporters, respectively; 0.2 ml membrane (10.3 g, 16.9 g or 6.2 g protein, respectively) and 0.2 ml buffer. After incubation, 37 Њ C for 40 minutes for the 5-HT transporter and 25 Њ C for 30 minutes for NE and DA transporters, the binding was terminated by rapid vacuum filtration over Whatman GF/B filters (presoaked in 0.5% polyethylenimine) and the filters were washed four times with cold 50 mM Tris Cl buffer, pH 7.4. The filters were then placed in vials containing liquid scintillation fluid and radioactivity was measured by liquid scintillation spectrometry. Non-specific binding was determined by including separate samples of 1 M duloxetine, 10 M desipramine or 10 M nomifensine, for 5-HT, NE and DA transporters, respectively.
For binding to rat monoamine transporters, rat frontal cortical membranes were prepared by ABS, Inc. (Wilmington, DE) . Briefly, male Sprague-Dawley rats were killed by decapitation, the brains rapidly removed and the frontal cortex was dissected over ice. The tissue was homogenized in 40 volumes of ice chilled 50 mM Tris-Cl, pH 7.4, and centrifuged at 39,800 ϫ g for 10 minutes and the supernatant decanted. This process was repeated twice and the resulting homogenate was incubated at 30 Њ C for 20 minutes, then centrifuged as before. The final pellets were immediately frozen at Ϫ 80 Њ C. After thawing, aliquots of the membranes containing 50 g protein were incubated with various concentrations of drugs, either [ 3 H]-paroxetine (0.2 nM) or [ 3 H]-nisoxetine (1 nM), respectively, in 50 mM Tris Cl, pH 7.4, 150 mM NaCl (300 mM NaCl for nisoxetine) and 5 mM KCl buffer. After a 30-min incubation at room temperature, the reaction mixtures were filtered under vacuum with a cell harvester fitted with a GF/B filter (Brandel, Gaithersburg, MD). The filters were then placed in vials containing liquid scintillation fluid and radioactivity was measured by liquid scintillation spectrometry. Samples containing 1 M duloxetine and 10 M desipramine were included to assess non-specific binding to the serotonin and norepinephrine transporter, respectively.
Monoamine Uptake into Synaptosomes
Uptake of monoamines was determined according to method of Wong et al. (1993) . Accumulation of radioactivity at 4 Њ C represented non-specific uptake and was subtracted from each sample. The uptake of 5-HT into platelets from humans was conducted according to the method of Wong et al. (1993) .
Ex vivo Uptake
Ex vivo uptake was determined in groups of five Sprague-Dawley male rats (Harlan Sprague-Dawley) weighing 100-150 gm according to the method of Wong et al. (1993) . Briefly, the rats were treated with specified doses of drugs either by the subcutaneous (s.c.) or oral route for one hour and then euthanized by decapitation. Uptake of [ 
Ex vivo Binding
Sprague-Dawley male rats in groups of five weighing about 100-150 gm were administered s.c. either saline vehicle or varying doses of drugs and the rats were euthanized one hour after the injection. The cerebral cortices were quickly dissected and frozen on dry ice. After weighing, the tissue was homogenized in 10 volumes of 50 mM Tris Cl buffer, pH 7.4, and frozen overnight at Ϫ 80 Њ C. After thawing, the whole homogenates were preincubated at 37 Њ C for 30 minutes. Ex vivo binding of [ 
Blockade of p-chloramphetamine (p-CA) and 6-hydroxydopamine (6-OHDA) effects
The 5-HT selective neurotoxin p-chloramphetamine hydrochloride (p-CA) was dissolved in distilled H 2 O for i.p. administration. Male Sprague-Dawley rats in groups of five weighing 180-230 grams were injected with p-CA (10 mg/kg i.p.) two hours before being killed by cervical dislocation. Vehicle, duloxetine, or venlafaxine were injected one hour prior to p-CA. The tissues were quickly removed, dissected, frozen on dry ice and stored at -70 Њ C until assayed. 6-Hydroxydopamine hydrobromide (6-OHDA), a catecholaminergic neurotoxin, was dissolved in 0.1% ascorbic acid. Duloxetine or venlafaxine were injected i.p. at various doses one hour prior to intracerebroventricular injection of 6-OHDA (50 g/rat) and the rats were killed one week later. Whole brain 5-HT concentrations in the p-CA study and NE concentrations in the hypothalamus for the 6-OHDA study were measured using high pressure liquid chromatography with electrochemical detection (HPLC-EC) as previously described (Fuller and Perry 1989) .
Determination of Binding to Neuronal Receptors and Monoamine Oxidase Activity
Binding to dopamine D 2 , opiate, muscarinic, histamine H 1 , ␣ 1 -adrenergic and ␣ 2 -adrenergic receptors was determined using [ H]-clonidine, respectively, as previously described (Wong et al. 1993) . The binding to human 5-HT receptor subtypes was determined according to published methods (5-HT 1A and 5-HT 1E , Zgombick et al. 1991 ; 5-HT 1B and 5-HT 1D , Weinshank et al. 1992 ; 5-HT 1F , Adham et al. 1993 ; 5-HT 2A , 5-HT 2B , 5-HT 2C , Wainscott et al. 1996 ; 5-HT 6 , Boess et al. 1997; 5-HT 7 , Bard et al. 1993 (Fuller et al. 1970 ).
Data Analysis
Inhibition curves for in vitro studies were analyzed by nonlinear least-squares curve fitting to obtain IC 50 values. The K i values were calculated from IC 50 and K d values according to the method of Cheng and Prusoff (1973) . The K m values for 5-HT, NE and DA uptake were 8for the 5-HT, NE and DA transporters were 0.18, 2.5 and 22.8 nM, respectively. Statistical analyses for in vivo studies were done by analysis of variance using Tukey's Honestly Significant Difference method ( p Ͻ .05) based on the mean square error.
Drugs
Duloxetine, (ϩ)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propamine HCl or oxalate) and venlafaxine (1-[2-(dimethyl-amino)-1-(4-methoxyphenyl)-ethyl] cyclohexanol hydrochloride) were provided by the Lilly Research Laboratories, Indianapolis IN. 6-Hydroxydopamine hydrobromide and p-CA HCl, were purchased from Sigma Chemical Co. (St Louis, MO). All other chemicals were reagent grade.
RESULTS
Duloxetine and venlafaxine dose-dependently inhibited binding of the serotonin transporter radioligand [ 3 H]-paroxetine to membranes from cells transfected with the human 5-HT transporter (Fig. 1) Table 1 .) The K i values for inhibition of uptake of [ 3 H]-5-HT into rat cerebral cortical synaptosomes was 4.6 Ϯ 1.1 (Wong et al. 1993 ) and 77 Ϯ 2 nM for duloxetine and venlafaxine, respectively ( (Table 1) .
Duloxetine inhibited binding to human 5-HT 6 and 5-HT 2A receptor subtypes with K i values of 419 Ϯ 89 and 504 Ϯ 87 nM, respectively and had affinity of Ͼ900 nM for the other 5-HT receptor subtypes examined (Table 2). Similarly, venlafaxine had relatively low affinity for the 5-HT receptor subtypes examined (Table 2) . Neither compound had significant affinity for muscarinic, dopamine D 2 , ␣ 1 -, ␣ 2 -adrenergic or histamine H 1 receptors and did not appreciably inhibit monoamine oxidase type A or B (Table 2) . Further, duloxetine and venlafax- H]-DA was in synaptosomes from rat cerebral cortex, hypothalamus, and striatum, respectively. All values determined from three or more independent experiments with at least 6 concentrations of drug in triplicate. *Data from Wong et al. (1993). ineneither at 1 M concentration did not significantly inhibited radioligand binding to 52 other neurotransmitter receptors, ion channel receptors, second messenger receptors, additional neurotransmitter transporters or brain/gut peptide receptors (Table 3) .
The ability of duloxetine and venlafaxine to penetrate into the brain after systemic administration and interact with monoamine transporters was investigated using ex vivo binding to transporters and in vivo blockade of transporter-dependent neurotoxins. Duloxetine and venlafaxine penetrated into the brain and dosedependently inhibited ex vivo binding of [ Table 4 ). Duloxetine inhibited 5-HT ex vivo uptake with ED 50 values of 12.2 Ϯ 1.6 mg/kg p.o. and 2.0 mg/kg s.c., respectively, and NE ex vivo uptake with ED 50 values of 14.6 Ϯ 2.3 p.o. and 3 mg/kg s.c., respectively (Wong et al. 1993 ). Thus, duloxetine was 66 and 77 times more potent at inhibiting 5-HT and NE transporters than venlafaxine. The depletion of 5-HT in rat brain induced by p-CA was antagonized dose-dependently by duloxetine and venlafaxine with ED 50 values of 2.3 and 5.9 mg/kg i.p., respectively (Table 4 , Fig. 4, Panel A) . The depletion of norepinephrine levels in rat hypothalamus induced by 6-OHDA was dose-dependently blocked by duloxetine and venlafaxine with ED 50 values of 12 and 94 mg/kg i.p., respectively (Table 4 , Fig. 4, Panel B) .
The NE/5-HT selectivity ratio of duloxetine for human transporters was 9.4 and 7.2 for rat transporters, respectively (Table 5 ). The NE/5-HT selectivity ratio of venlafaxine was 30 and 23 for human and rat transporters, respectively. The ratio for blockade of 5-HT and NE uptake processes in rat synaptosomes was 3.5 and 7 for duloxetine and venlafaxine, respectively. In vivo, the NE/5-HT selectivity ratio for ex vivo transporter binding was 23 and 27 for duloxetine and venlafaxine, respectively. The ratio for blockade of 6-OHDA/p-CA was 5.2 and 16 for duloxetine and venlafaxine, respectively.
DISCUSSION
In the present study the ability of duloxetine and venlafaxine to block 5-HT and NE transporters in vitro and in vivo was compared. Duloxetine potently inhibited binding to the human 5-HT transporters with a K i value of 0.8 nM, whereas venlafaxine was 106 times less potent. Duloxetine also potently inhibited binding to the human NE transporter with a K i value of 7.5 nM and venlafaxine inhibited binding to the human NE transporter with a K i value of 2480 nM. Thus, venlafaxine inhibited binding to the NE transporter with 331 times lower affinity than duloxetine. Duloxetine and venlafaxine inhibited binding to the rat 5-HT and NE transporters with similar affinities to that of human transporters. The K i values of duloxetine for inhibition of 5-HT and NE transporters are in agreement with previously reported values in rat tissue (Béïque et al. 1998; Wong et al. 1993 ) and for venlafaxine in human and rodent tissue (Tatsumi et al. 1997; Béïque et al. 1998) . The selectivity ratios of duloxetine and venlafaxine for NE/ 5-HT blockade of human transporters were 9.4 and 30, respectively. Similar selectivity ratios of 7.2 and 23 for rat NE and 5-HT transporters, respectively, were determined. Relative to their affinity for 5-HT transporters, neither drug had high affinity for the human dopamine transporter.
The dual uptake inhibitors also inhibited in vitro uptake of monoamines in synaptosomes of rat brain. Duloxetine inhibited 5-HT, NE and DA uptake with K i values of 4.6, 16 and 369 nM, respectively, in good agreement with values obtained with transporter binding in rat tissue. Venlafaxine inhibited uptake with 17, 34 and 17-fold lower potency, respectively. The NE/ 5-HT selectivity ratios of duloxetine and venlafaxine for rat synaptosomal uptake was 3.5 and 7, respectively.
Non-selective interaction of uptake inhibitors with neuronal receptors may increase their side effect potential and new drugs in this class have been designed to have low affinity for these receptors . Duloxetine and venlafaxine demonstrated remarkably low levels of interaction with a number of neuronal receptors, suggesting that they would be free from side effects due to cholinergic, histaminic, dopaminergic, and adrenergic blockade. Duloxetine and venlafaxine also blocked uptake transporters in vivo in rats. Duloxetine blocked ex vivo 5-HT and NE transporter binding with ED 50 values of 0.03 and 0.7 mg/kg s.c. Venlafaxine was 67 and 77-fold less potent than duloxetine at inhibiting 5-HT and NE ex vivo transporter binding. Duloxetine with comparable potency blocked ex vivo uptake of 5-HT and NE into brain homogenates after s.c. and oral administration, although higher doses were required to block ex vivo uptake than ex vivo transporter binding, consistent with lower affinity at uptake blockade than inhibition of transporter binding. Duloxetine blocked transporterdependent depletion of 5-HT concentrations in rat brain by p-CA with an ED 50 value of 2.3 mg/kg i.p., demonstrating in vivo blockade of the 5-HT transporter (Fuller et al. 1994) . Similarly, venlafaxine blocked p-CAinduced 5-HT depletion, but was 2.6 times less potent. Blockade of NE transporter-dependent 6-OHDA-induced depletion of NE concentrations in rat hypothalamus was used to evaluate blockade of the NE transporter in vivo (Fuller et al. 1994) . Duloxetine and venlafaxine blocked 6-OHDA-induced NE depletion with ED 50 values of 12 and 94 mg/ kg i.p., respectively. The selectivity ratio for blocking NE/5-HT transporter-dependent effects in vivo was 5.2 and 16-fold, respectively. Thus, both drugs penetrate into the brain and inhibit both 5-HT and NE uptake processes, although considerably higher doses of venlafaxine were needed to block the NE transporter.
Thus, duloxetine compared to venlafaxine had higher affinity and more potent blockade of 5-HT and NE transporters in vitro and in vivo. The results are in general agreement with previously reported results on the two compounds. For example, venlafaxine was found to have 10-fold higher potency for prolonging suppression of dorsal hippocampal CA 3 neuronal firing by microiontophoretically applied 5-HT versus NE (Béïque et al. 1998) . Venlafaxine was also 3-fold more potent at suppressing spontaneous firing activity of 5-HT neurons in the dorsal raphe compared to suppressing NE neuronal activity in locus coeruleus (Béïque et al. 1999) , although venlafaxine did not completely suppress firing in the locus coeruleus, unlike other NE uptake inhibitors including duloxetine (Kasamo et al. 1996) . In the same electrophysiological paradigm, duloxetine was 4.8-fold more potent at inhibiting spontaneously firing activity in the dorsal raphe 5-HT neurons than inhibiting NE neurons in the locus coeruleus (Kasamo et al. 1996) . The data presented in this paper demonstrate at least a 16-fold difference for in vivo potency of venlafaxine to block 5-HT and NE transporterspecific neurotoxins, whereas there was only 5-fold difference for duloxetine. The discrepancy between the affinity of venlafaxine for blocking 5-HT and NE transporters versus the potency of suppression of firing activity of cell bodies may be related to the different routes of administration, formation of active metabolites and/or sensitivity of firing of neurons. Overall, venlafaxine was consistently more potent in vivo than would be predicted from in vitro binding data, possibly due to relatively low protein binding or other bioavailability attributes (Troy et al. 1996) .
Results from microdialysis studies indicate that duloxetine increases extracellular 5-HT and NE levels in frontal cortex and hypothalamus (Gobert et al. 1997; Kihara and Ikeda 1995; Engleman et al. 1995) in a similar dose range to doses that block both 5-HT and NE transporters, consistent with uptake blockade increasing extracellular levels of the neurotransmitters. Selective blockade of 5-HT and NE autoreceptors markedly augmented the duloxetine-induced increase of extracellular levels of 5-HT and NE, respectively, suggesting that increased levels of monoamines activated inhibitory autoreceptors (Engleman et al. 1996; Millan et al. 1998; Gobert et al. 1997) . This is supported by the previously mentioned reports of inhibition of spontaneous firing activity of dorsal raphe 5-HT and locus ceruleus NE neurons by duloxetine (Kasamo et al. 1996) . Duloxetine was active in several rodent behavior models of NE uptake inhibition including reserpine-induced hypothermia and tetrabenazine-induced ptosis and models for augmentation of 5-HT responses such as 5-hydroxytryptophan-induced head movements (Katoh et al. 1995) . Duloxetine and venlafaxine also produced effects in the rat forced swim test consistent with blockade of multiple neurotransmitter systems (Reneric and Lucki 1998) .
In summary, both duloxetine and venlafaxine inhibit 5-HT and NE uptake processes and transporter binding in vitro and in vivo. However, duloxetine has 100-fold or higher affinity for human and rat 5-HT transporters and at least 300-fold higher affinity for NE transporters in vitro compared to venlafaxine. In vivo, duloxetine blocks 5-HT and NE transporter dependent monoamine depletion by neurotoxins with 2.5 and 7.8-fold higher potency than venlafaxine. Overall, these data are consistent with microdialysis data indicating that duloxetine increases 5-HT and NE extracellular levels at similar doses . Clinical testing of these compounds is required to determine if the supplemental addition of blockade of NE as well as 5-HT uptake inhibition enhances the efficacy and decreases the delay in onset of antidepressant activity compared to SSRIs. 6-hydroxydopamine (6-OHDA) was injected intracerebroventricularly (50 g/rat) one hour after injection of vehicle or various i.p. doses of duloxetine or venlafaxine. The rats were euthanized one week after the 6-OHDA injection. The levels of 5-HT in whole brain and NE in hypothalamus were determined by HPLC-EC. Data are expressed as % antagonism Ϯ SEM of the reduction in monoamine levels by the neurotoxin for five rats per group. The concentration of 5-HT in brain of control-and p-CA-treated rats was 2.42 Ϯ 0.10 and 1.11 Ϯ 0.06 nmol/gm, respectively. The concentration of NE in hypothalamus of control-and 6-OHDAtreated rats was 5.75 Ϯ 0.31 and 2.70 Ϯ 0.45 nmol/gm, respectively. *ϭ p Ͻ .05. Data from Table 1 and Table 4 , ND ϭ not determined.
